Bibliography
- De Clercq E. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). Adv Pharmacol 2013;67:317–58
- Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 2010;53:521–38
- De Clercq E. Dancing with chemical formulae of antivirals: a personal account. Biochem Pharmacol 2013;86:711–25
- De Clercq E. Dancing with chemical formulae of antivirals: A panoramic view (Part 2). Biochem Pharmacol 2013;86:1397–410
- De Clercq E. Curious discoveries in antiviral drug development: the role of serendipity. Med Res Rev 2015;35:698–719
- De Clercq E. Antivirals: past, present and future. Biochem Pharmacol 2013;85:727–44
- Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. Expert Opin Pharmacother 2011;12:31–46
- Zhang J, Crumpacker C. Eradication of HIV and Cure of AIDS, Now and How? Front Immunol 2013;4:337
- Kang D, Song Y, Chen W, et al. “Old dogs with new tricks”: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets. Mol Biosyst 2014;10:1998–2022
- Hennig M, Ruf A, Huber W. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery. Top Curr Chem 2012;317:115–43
- Murray CW, Rees DC. The rise of fragment-based drug discovery. Nat Chem 2009;1:187–92
- Chessari G, Woodhead AJ. From fragment to clinical candidate--a historical perspective. Drug Discov Today 2009;14:668–75
- Gozalbes R, Carbajo RJ, Pineda-Lucena A. Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery. Curr Med Chem 2010;17:1769–94
- Tiefenbrunn T, Forli S, Baksh MM, et al. Small molecule regulation of protein conformation by binding in the Flap of HIV protease. ACS Chem Biol 2013;8:1223–31
- Tiefenbrunn T, Forli S, Happer M, et al. Crystallographic fragment-based drug discovery: use of a brominated fragment library targeting HIV protease. Chem Biol Drug Des 2014;83:141–8
- Deng N, Forli S, He P, et al. Distinguishing binders from false positives by free energy calculations: fragment screening against the flap site of HIV protease. J Phys Chem B 2015;119:976–88
- Kunze J, Todoroff N, Schneider P, et al. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors. J Chem Inf Model 2014;54:987–91
- Geitmann M, Elinder M, Seeger C, et al. Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. J Med Chem 2011;54:699–708
- Bauman JD, Patel D, Arnold E. Fragment screening and HIV therapeutics. Top Curr Chem 2012;317:181–200
- Bauman JD, Patel D, Dharia C, et al. Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening. J Med Chem 2013;56:2738–46
- La J, Latham CF, Tinetti RN, et al. Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. Proc Natl Acad Sci U S A 2015;112:6979–84
- Rhodes DI, Peat TS, Vandegraaff N, et al. Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design. Antivir Chem Chemother 2011;21:155–68
- Peat TS, Rhodes DI, Vandegraaff N, et al. Small molecule inhibitors of the LEDGF site of human immunodeficiency virus integrase identified by fragment screening and structure based design. PLoS One 2012;7:e40147
- Chu S, Gochin M. Identification of fragments targeting an alternative pocket on HIV-1 gp41 by NMR screening and similarity searching. Bioorg Med Chem Lett 2013;23:5114–18
- Tiefenbrunn T, Stout CD. Towards novel therapeutics for HIV through fragment-based screening and drug design. Prog Biophys Mol Biol 2014;116:124–40
- Congreve M, Carr R, Murray C, et al. A ’rule of three’ for fragment-based lead discovery? Drug Discov Today 2003;8:876–7
- Song Y, Zhan P, Liu X. Heterocycle-thioacetic acid motif: a privileged molecular scaffold with potent, broad-ranging pharmacological activities. Curr Pharm Des 2013;19:7141–54
- Song Y, Zhan P, Zhang Q, et al. Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. Curr Pharm Des 2013;19:1528–48
- Song Y, Chen W, Kang D, et al. “Old friends in new guise”: exploiting privileged structures for scaffold re-evolution/refining. Comb Chem High Throughput Screen 2014;17:536–53
- Chen H, Zhou X, Wang A, et al. Evolutions in fragment-based drug design: the deconstruction-reconstruction approach. Drug Discov Today 2015;20:105–13
- Song Y, Xu H, Chen W, et al. 8-Hydroxyquinoline: a privileged structure with broad-ranging pharmacological potentials. MedChemComm 2015;6:61–74
- Serrao E, Debnath B, Otake H, et al. Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction. J Med Chem 2013;56:2311–22
- Zhan P, Chen X, Li D, et al. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 2013;33:E1–E72
- Zhan P, Liu X. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). Expert Opin Ther Pat 2011;21:717–96
- Li X, Zhang L, Tian Y, et al. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014). Expert Opin Ther Pat 2014;24:1199–227
- Song Y, Fang Z, Zhan P, et al. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update. Curr Med Chem 2013;21:329–55
- Zhan P, Liu X, Li Z. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 Update. Curr Med Chem 2009;16:2876–89
- Zhan P, Liu X, Li Z, et al. Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem 2009;16:3903–17
- Liu Y, Zhou E, Yu K, et al. Discovery of a novel CCR5 antagonist lead compound through fragment assembly. Molecules 2008;13:2426–41
- Viegas-Junior C, Danuello A, da Silva Bolzani V, et al. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 2007;14:1829–52
- Jones LH, Allan G, Barba O, et al. Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. J Med Chem 2009;52:1219–23
- Liu Z, Chen W, Zhan P, et al. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. Eur J Med Chem 2014;87:52–62
- Manetsch R, Krasiński A, Radić Z, et al. In situ click chemistry: enzyme inhibitors made to their own specifications. J Am Chem Soc 2004;126:12809–18
- Thirumurugan P, Matosiuk D, Jozwiak K. Click chemistry for drug development and diverse chemical-biology applications. Chem Rev 2013;113:4905–79
- Whiting M, Muldoon J, Lin YC, et al. Inhibitors of HIV-1 protease by using in situ click chemistry. Angew Chem Int Ed Engl 2006;45:1435–9
- Brik A, Wu CY, Wong CH. Microtiter plate based chemistry and in situ screening: a useful approach for rapid inhibitor discovery. Org Biomol Chem 2006;4:1446–57
- Brik A, Muldoon J, Lin YC, et al. Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors. ChemBioChem 2003;4:1246–8
- Whiting M, Tripp JC, Lin YC, et al. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization. J Med Chem 2006;49:7697–710
- Brik A, Lin YC, Elder J, et al. A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors. Chem Biol 2002;9:891–6
- Lee SG, Chmielewski J. Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors. Chem Biol 2006;13:421–6
- Liang FS, Brik A, Lin YC, et al. Epoxide opening in water and screening in situ for rapid discovery of enzyme inhibitors in microtiter plates. Bioorg Med Chem 2006;14:1058–62
- Joseph-McCarthy D. Challenges of fragment screening. J Comput Aided Mol Des 2009;23:449–51
- Navratilova I, Hopkins AL. Fragment screening by surface plasmon resonance. ACS Med Chem Lett 2010;1:44–8
- Elinder M, Geitmann M, Gossas T, et al. Experimental validation of a fragment library for lead discovery using SPR biosensor technology. J Biomol Screen 2011;16:15–25
- Konteatis ZD. In silico fragment-based drug design. Expert Opin Drug Discov 2010;5:1047–65
- Mortier J, Rakers C, Frederick R, et al. Computational tools for in silico fragment-based drug design. Curr Top Med Chem 2012;12:1935–43
- Ferenczy GG, Keserű GM. How are fragments optimized? A retrospective analysis of 145 fragment optimizations. J Med Chem 2013;56:2478–86
- Öster L, Tapani S, Xue Y, et al. Successful generation of structural information for fragment-based drug discovery. Drug Discov Today 2015. [Epub ahead of print]
- Zhan P, Itoh Y, Suzuki T, et al. Strategies for the discovery of target-specific or isoform-selective modulators. J Med Chem 2015. [Epub ahead of print]
- Wang X, Huang B, Liu X, et al. Discovery of bioactive molecules from CuAAC click chemistry-based combinatorial libraries. Drug Discovery Today 2015; revised